Indo Us Bio-Tech FY26 Results

Indo Us Bio-Tech Limited reported standalone audited financial results for the year ended March 31, 2026. The company's revenue from operations increased by 6.36% to ₹110.44 crore, up from ₹103.83 crore in the previous fiscal year.

However, net profit saw a significant decline of 19.36%, falling to ₹13.12 crore from ₹16.27 crore in FY25. Basic Earnings Per Share (EPS) also decreased by 19.36% to ₹6.54. Total assets grew by 36.04% to ₹133.10 crore.

Reader Takeaway: Revenue grew, but rising costs impacted profit; auditor concerns warrant attention.

What just happened

Indo Us Bio-Tech announced its audited financial results for the fiscal year ending March 31, 2026. The company reported a consolidated revenue of ₹110.44 crore, an increase from ₹103.83 crore in the prior year. Despite the revenue growth, net profit decreased to ₹13.12 crore from ₹16.27 crore, a reduction of 19.36%. This was attributed to a rise in total expenses to ₹96.57 crore from ₹87.49 crore, growing faster than revenue.

Why this matters

The decline in profitability, despite top-line growth, signals potential pressure on margins or increased operational costs. Investors will be keen to understand the reasons behind the faster rise in expenses compared to revenue. The auditor's remarks about pending confirmations and cash sales verification also raise questions about internal controls and transparency.

The backstory

In the previous fiscal year (FY25), Indo Us Bio-Tech had reported a net profit of ₹16.27 crore on revenues of ₹103.83 crore. The company has been expanding its asset base, as indicated by the 36.04% increase in total assets for FY26.

What changes now

Investors need to closely monitor the company's strategies for cost management and operational efficiency. The concerns raised by the auditors will likely lead to increased scrutiny of the company's accounting practices and internal processes.

Risks to watch

Key risks include the potential impact of ongoing income tax disputes, with a notable demand of ₹1.42 crore for assessment year 2020-21. The auditor's highlighted issues regarding pending confirmations for receivables, payables, loans, and advances, along with verification of cash sales, are also significant watch points that could indicate underlying operational or control weaknesses.

Peer comparison

(No specific peer comparison data was provided in the filing.)

Context metrics (time-bound)

• Revenue from Operations (FY26): ₹110.44 crore (+6.36% vs FY25)
• Net Profit (FY26): ₹13.12 crore (-19.36% vs FY25)
• Basic EPS (FY26): ₹6.54 (-19.36% vs FY25)
• Total Assets (FY26): ₹133.10 crore (+36.04% vs FY25)

What to track next

Investors should look for management's commentary on the factors driving increased expenses and their plans for cost control. Progress on resolving the tax disputes and addressing the auditor's concerns regarding pending confirmations and cash sales verification will be crucial to monitor.